JERSEY CITY, N.J., Dec. 17, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq:SCYX) today announced the pricing of its underwritten public offering of common stock, pre-funded warrants and warrants. The shares and warrants are being sold at a public offering price of $6.25 per share and accompanying warrants, and the pre-funded warrants are being sold at a public offering price of $6.249 per pre-funded warrant and accompanying warrants. The gross offering proceeds to SCYNEXIS from this offering are expected to be approximately $85.0 million, before deducting the underwriting discount and other estimated offering expenses, and excluding the exercise of any pre-funded warrants or warrants. All of the shares of common stock, pre-funded warrants and warrants are being offered by SCYNEXIS.

Follow this link:
SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

CALGARY, Alberta, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Biosenta’s stock closed at 0.75 CAD +0.37 (97.37%). This marked the third day of Alberta’s Province wide Covid-19 lockdown. This is in step with Biosenta’s strategic business plan grow the company and to capture the growing trend for safe, consumer, commercial and industrial disinfectant with anti-microbial compounds. This comes on the eve of Biosenta receiving the patent for Canada.

View original post here:
Biosenta growth milestone

LONDON and NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces it has applied to list its ordinary shares ("Ordinary Shares") on the standard listing segment of the Official List of the Financial Conduct Authority (“FCA”) (the "Official List") and admission to trading on the London Stock Exchange plc's (the "London Stock Exchange") main market ("Main Market") for listed securities (together, "Admission"). The Board has taken this decision as it believes that a standard listing will afford Tiziana greater flexibility in pursuing its strategy as an international company.

See original here:
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading...

New intellectual property facilitates the precise control and modulation of cannabinoid production New intellectual property facilitates the precise control and modulation of cannabinoid production

Read the rest here:
22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD,...

– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 –

Continued here:
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that it commenced an underwritten public offering of units consisting of its common stock, par value $0.001 per share (the “Common Stock”), and its Series D convertible preferred stock (the “Series D Preferred Stock”). All securities to be sold in the offering are to be sold by VistaGen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

See the original post:
VistaGen Therapeutics Announces Proposed Underwritten Public Offering

PRA’s remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionality PRA’s remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionality

See the original post:
PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilities

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx’s existing bone franchise

Here is the original post:
Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that it has appointed Meeta Chatterjee, Ph.D., to its Board of Directors.

Here is the original post:
Editas Medicine Names Meeta Chatterjee, Ph.D., to Board of Directors

PRESS RELEASE

More here:
Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%

Attachment

View original post here:
Availability of the Q4 2020 Memorandum for modelling purposes

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection after the Data Safety Monitoring Board (DSMB) performed a third interim analysis on the trial’s first 180 patients. The trial was powered to achieve a primary endpoint of 43% reduction in mortality at 30 days for treatment with remestemcel-L on top of maximal care in a trial of 300 patients. This projected mortality reduction was based on pilot data observed during the initial stages of the pandemic when control mortality rates were exceedingly high and prior to new evolving treatment regimens that have reduced disease mortality in ventilated patients. The DSMB reported that there were no safety concerns and noted that the trial is not likely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment. The DSMB recommended that the trial complete with the currently enrolled 223 patients, and that all be followed-up as planned.

Originally posted here:
Mesoblast Update on COVID-19 ARDS Trial

FORT LAUDERDALE, Fla., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has collected a series of case studies from several leading U.S. hospitals which highlight the advantages of utilizing its Pure-Vu System to successfully complete emergent or challenging colonoscopies for patients with inadequately prepared colons. The case studies are now available on the Motus GI website (click here).

Read more from the original source:
Motus GI Announces Clinical Compendium of Pure-Vu System Patient Case Studies As Reported by Several Leading U.S. Hospitals

Presentation at the American Society for Microbiology NGS Conference highlights utility of PacBio’s highly accurate long-read sequencing platform in disease surveillance Presentation at the American Society for Microbiology NGS Conference highlights utility of PacBio’s highly accurate long-read sequencing platform in disease surveillance

See original here:
SARS-CoV-2 Viral Genome Sequencing Data Presented from Research Using Pacific Biosciences Technology

Sydney, AUSTRALIA, Dec. 16, 2020 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, has prioritised the recommencement of the process of scaling up the manufacturing of its lead product candidate eftilagimod alpha (“efti” or “IMP321”).

Follow this link:
Immutep Upscales Efti Manufacturing

Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions with regulatory authorities.

Excerpt from:
Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide

BASEL, Switzerland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 46 new employees with a grant date of December 15, 2020 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08.

Read the original here:
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma

Excerpt from:
Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCVHS is Published in...

WOBURN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Abpro Corporation today announced the initiation of global Phase 2/3 registrational studies evaluating the safety, tolerability, efficacy, and pharmacokinetics of ABP 300, a human neutralizing antibody for the treatment of COVID-19 derived from patients who have recovered from the SARS-CoV2 infection. The first trial site has been opened with the remainder to follow in 2021. The Phase 1 clinical trial, which included 42 subjects, study results are expected in Q1 2021.

Continued here:
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19

CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.

Continue reading here:
Spero Therapeutics Added to the NASDAQ Biotechnology Index